Drug Profile
SEP 226330
Alternative Names: SEP-0226330; SEP-226330Latest Information Update: 22 Jul 2023
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Sepracor; Sumitomo Pharma America
- Class Antiparkinsonians
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease; Restless legs syndrome